



Trethera Corporation strengthens team with two new hires

Beverly Hills, CA, 20 June 2016 – Trethera, a biotechnology company focused on the discovery and development of innovative small molecules for the treatment of hematological and solid tumors announces the appointments of Dr. Neil Bajpayee and Shailaja Srinagesh to the positions of Associate Director of Scientific Affairs and Drug Development Project Manager respectively.

Dr. Neil Bajpayee joined Trethera in May 2016 as Associate Director of Scientific Affairs. His role includes the management of alliances with academic or pharmaceutical companies and business development activities. Most recently, Dr. Bajpayee worked for five years at UCLA's Office of Intellectual Property & Industry Sponsored Research as a Licensing Officer. At UCLA, he was responsible for managing a portfolio of life science intellectual property, negotiating licensing agreements, and evaluating new technologies from the university's life science divisions. Dr. Bajpayee has prior research experience spanning ten years from UCLA, Brookhaven National Laboratory in Upton, NY, and the Pennsylvania State University. Dr. Bajpayee received his B.S. in Microbiology from Penn State University, a Ph.D. in Molecular & Medical Pharmacology from UCLA, and is a registered Patent Agent with the USPTO.

Shailaja Srinagesh joined Trethera in June 2016 in the role of Drug Development Project Manager. Ms. Srinagesh previously worked at Genentech, Inc., South San Francisco, as a Senior Scientific Supervisor where she managed the early stage research pipeline for large molecule programs in cancer immunology, discovery biology, metabolism and neurobiology. She brings eleven years of project and alliance management experience in diverse therapeutic indications gained in various roles spanning Genentech, a member of the Roche group, start-up firms such as Ambrx Inc., in La Jolla, Kent Biosciences in San Diego and The Central Drug Research Institute (CDRI) in Lucknow, India. Ms. Srinagesh received her M.Sc. in Biological Sciences from Birla Institute of Technology & Science (BITS), Pilani, India and an M.S. in Cell & Molecular Biology from San Diego State University, San Diego.

Dr Johanna Holldack, CEO of Trethera commented:

“As Trethera continues to grow into a clinical stage company and develop innovative therapeutics in the oncology field, the recruitment of experienced talent is essential. We welcome Neil and Shailaja who further strengthen our team by bringing valuable research and business expertise to help drive our candidates towards the clinic.”

-End-

For more information, please contact:

Trethera
Dr. Johanna Holldack, CEO

Tel: +1 310 997 278
jholldack@trethera.com

Instinctif Partners
Dr. Christelle Kerouedan

Tel: +44 (0)20 7457 2020
trethera@instinctif.com

NOTES TO EDITORS

About Trethera

Trethera is a biotechnology company focused on the discovery and development of innovative small molecules that precisely control nucleotide metabolism and DNA replication and integrity for the treatment of malignant diseases.



The Company is building a pipeline of oncology products by harnessing its proprietary technology platform which is based on regulatory checkpoints in the complex system of nucleotide metabolism.

Trethera's lead compound DI-87 (TRE-515) is advancing through pre-clinical development with programs in both Leukemia and Solid Tumors. It is an oral small molecule inhibitor of Deoxycytidine Kinase, an important enzyme implicated in cancer cell proliferation. TRE-515 is being developed as a combination therapy and it is anticipated that the first clinical trial will commence in the second half of 2017.

The Company has a strong and growing patent position and an exclusive license from UCLA for patents relating to its platform and Deoxycytidine Kinase Inhibitors. The research behind the technology and products has received competitive grants and departmental funds totaling millions of dollars over the past eight years.

Trethera is located in California, U.S.

For more information, please visit the website: www.trethera.com.